Skip to main content

PRESS RELEASES

Date Title  
Toggle Summary Seres Therapeutics to Present at the Stifel 2019 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 14, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19 at 9:10 a.m. ET . A live audio webcast of the presentation will be available under the
Toggle Summary Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update
– Two late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020 – – Debt facility secured, providing up to $50 million in additional capital; Corporate resources are expected to support operations into Q2 2021 – – Conference call at 8:30 a.m.
Toggle Summary Seres Therapeutics to Host Third Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on November 5, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 31, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on November 5, 2019 at 8:30 a.m. ET to discuss third quarter 2019 results and provide a general business update.
Toggle Summary Seres Therapeutics Appoints Stephen Berenson to its Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 6, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced the appointment of Stephen Berenson to its Board of Directors. Mr. Berenson is a Managing Partner at Flagship Pioneering and previously spent his career as an investment banker at J.P.
Toggle Summary Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update
- Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs – - Completed public offering of common stock, raising net proceeds of $61M and extending the operating runway into 2021 – - Conference call at 8:00 a.m.
Toggle Summary Seres Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present at the Canaccord Genuity 39 th Annual Growth Conference in Boston, MA on Wednesday, August 7 at 8:00 a.m. ET . A live audio webcast of the presentation will be available
Toggle Summary Seres Therapeutics to Host Second Quarter 2019 Financial Results and Operational Progress Conference Call and Webcast on August 6, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that management will host a conference call and live audio webcast on August 6, 2019 at 8:00 a.m. ET to discuss second quarter 2019 results and provide a general business update.
Toggle Summary Seres Therapeutics Issues Statement Regarding U.S. Food and Drug Administration Safety Alert Related to Use of Fecal Microbiota Transplantation
FDA alert does not impact Seres’ microbiome investigational therapeutic candidates CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 19, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) (“Seres”) today provided a statement on a safety alert from the U.S. Food and Drug Administration ( FDA ) regarding
Toggle Summary Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 13, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today
Toggle Summary Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 12, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today

Back to top